$SVRA
Savara Inc

2024 Q3 Form 10-Q Financial Statement

#000095017024095403 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.013M $5.540M
YoY Change 44.89% 67.78%
% of Gross Profit
Research & Development $20.31M $17.62M
YoY Change 46.47% 97.7%
% of Gross Profit
Depreciation & Amortization $33.00K $33.00K
YoY Change 10.0% 312.5%
% of Gross Profit
Operating Expenses $26.36M $23.19M
YoY Change 46.07% 89.76%
Operating Profit -$26.36M -$23.19M
YoY Change 46.07% 89.76%
Interest Expense $2.129M $1.072M
YoY Change 47.44% 51.2%
% of Operating Profit
Other Income/Expense, Net $2.109M $947.0K
YoY Change 45.95% 21.72%
Pretax Income -$24.25M -$22.24M
YoY Change 46.07% 94.38%
Income Tax
% Of Pretax Income
Net Earnings -$24.25M -$22.24M
YoY Change 46.08% 94.38%
Net Earnings / Revenue
Basic Earnings Per Share -$0.11 -$0.12
Diluted Earnings Per Share -$0.11 -$0.12
COMMON SHARES
Basic Shares Outstanding 164.6M 138.2M
Diluted Shares Outstanding 211.8M 182.6M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $219.4M $121.5M
YoY Change 30.39% 15.53%
Cash & Equivalents $21.40M $23.90M
Short-Term Investments $198.0M $97.65M
Other Short-Term Assets $5.796M $5.162M
YoY Change 544.0% 200.12%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $226.4M $127.7M
YoY Change 33.1% 18.34%
LONG-TERM ASSETS
Property, Plant & Equipment $206.0K $236.0K
YoY Change -25.63% -10.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.105M $1.106M
YoY Change -8.07% 24.55%
Total Long-Term Assets $12.42M $11.98M
YoY Change 3.72% 0.36%
TOTAL ASSETS
Total Short-Term Assets $226.4M $127.7M
Total Long-Term Assets $12.42M $11.98M
Total Assets $238.8M $139.7M
YoY Change 31.17% 16.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.609M $3.386M
YoY Change 43.18% 35.33%
Accrued Expenses $8.179M $7.900M
YoY Change 42.39% 133.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.79M $11.29M
YoY Change 42.68% 91.78%
LONG-TERM LIABILITIES
Long-Term Debt $26.55M $26.48M
YoY Change 1.03% 1.03%
Other Long-Term Liabilities $128.0K $169.0K
YoY Change -54.93% 745.0%
Total Long-Term Liabilities $26.68M $26.65M
YoY Change 0.43% 1.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.79M $11.29M
Total Long-Term Liabilities $26.68M $26.65M
Total Liabilities $39.47M $37.94M
YoY Change 11.09% 18.12%
SHAREHOLDERS EQUITY
Retained Earnings -$460.2M -$436.0M
YoY Change 21.97% 20.88%
Common Stock $659.3M $538.6M
YoY Change 25.63% 19.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $199.3M $101.7M
YoY Change
Total Liabilities & Shareholders Equity $238.8M $139.7M
YoY Change 31.17% 16.55%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$24.25M -$22.24M
YoY Change 46.08% 94.38%
Depreciation, Depletion And Amortization $33.00K $33.00K
YoY Change 10.0% 312.5%
Cash From Operating Activities -$22.67M -$22.50M
YoY Change 72.25% 118.99%
INVESTING ACTIVITIES
Capital Expenditures $3.000K $21.00K
YoY Change -92.5% -90.67%
Acquisitions
YoY Change
Other Investing Activities -$98.16M $29.56M
YoY Change 73.59% -3884.76%
Cash From Investing Activities -$98.17M $29.54M
YoY Change 73.47% -3036.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 118.3M 55.00K
YoY Change 58.26% -47.12%
NET CHANGE
Cash From Operating Activities -22.67M -22.50M
Cash From Investing Activities -98.17M 29.54M
Cash From Financing Activities 118.3M 55.00K
Net Change In Cash -2.519M 7.098M
YoY Change -150.28% -163.52%
FREE CASH FLOW
Cash From Operating Activities -$22.67M -$22.50M
Capital Expenditures $3.000K $21.00K
Free Cash Flow -$22.67M -$22.52M
YoY Change 71.75% 114.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001160308
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32157
dei Entity Registrant Name
EntityRegistrantName
Savara Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1318182
dei Entity Address Address Line1
EntityAddressAddressLine1
1717 Langhorne Newtown Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Langhorne
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19047
dei City Area Code
CityAreaCode
512
dei Local Phone Number
LocalPhoneNumber
614-1848
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
SVRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
164600603
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23864000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26585000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
97652000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
135734000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6178000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3628000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
127694000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
165947000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
236000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
270000
CY2024Q2 svra In Process Research And Development
InProcessResearchAndDevelopment
10634000
CY2023Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
10960000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1106000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
387000
CY2024Q2 us-gaap Assets
Assets
139670000
CY2023Q4 us-gaap Assets
Assets
177564000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3386000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3504000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7900000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7093000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11286000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10597000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26484000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26348000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
169000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
247000
CY2024Q2 us-gaap Liabilities
Liabilities
37939000
CY2023Q4 us-gaap Liabilities
Liabilities
37192000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
138199047
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
138199047
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
138143545
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
138143545
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
140000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
140000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
538429000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
533872000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-880000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-271000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-435958000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-393369000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
101731000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
140372000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139670000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
177564000
CY2024Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
17617000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8911000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
34424000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
17649000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5540000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3302000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11176000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6668000
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
33000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
65000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
16000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
23190000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
12221000
us-gaap Operating Expenses
OperatingExpenses
45665000
us-gaap Operating Expenses
OperatingExpenses
24333000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23190000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12221000
us-gaap Operating Income Loss
OperatingIncomeLoss
-45665000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24333000
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1072000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
709000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2425000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1474000
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-125000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
33000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-146000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
62000
CY2023Q2 svra Tax Credit Income
TaxCreditIncome
36000
svra Tax Credit Income
TaxCreditIncome
797000
svra Tax Credit Income
TaxCreditIncome
797000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
947000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
778000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3076000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2333000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-22243000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11443000
us-gaap Net Income Loss
NetIncomeLoss
-42589000
us-gaap Net Income Loss
NetIncomeLoss
-22000000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182584078
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182584078
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152796617
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152796617
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182567091
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182567091
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152778031
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152778031
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-113000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-98000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-333000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
32000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-25000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-60000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-276000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-46000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22381000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11601000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43198000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22014000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
140372000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000
CY2024Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2257000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-220000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-251000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-20346000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
121861000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2024Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2000
CY2024Q2 svra Adjustment To Additional Paid In Capital Reimbursement Of Commissions From Prior Issuance Of Common Stock Upon At The Market Sales Net
AdjustmentToAdditionalPaidInCapitalReimbursementOfCommissionsFromPriorIssuanceOfCommonStockUponAtTheMarketSalesNet
46000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2196000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-25000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-22243000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
101731000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
107778000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
864000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
130000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
14000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10557000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
98255000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
103000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
958000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-98000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-60000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11443000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
87715000
us-gaap Profit Loss
ProfitLoss
-42589000
us-gaap Profit Loss
ProfitLoss
-22000000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
65000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
16000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
71000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
31000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-146000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
62000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
135000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
135000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2495000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1837000
us-gaap Share Based Compensation
ShareBasedCompensation
4453000
us-gaap Share Based Compensation
ShareBasedCompensation
1822000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2677000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-377000
svra Increase Decrease In Noncurrent Assets
IncreaseDecreaseInNoncurrentAssets
814000
svra Increase Decrease In Noncurrent Assets
IncreaseDecreaseInNoncurrentAssets
792000
svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
566000
svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
12000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43139000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22298000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
229000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
34138000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
60872000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
74500000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
54000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
40331000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7101000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
62000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
131000
svra Reimbursement Of Commissions From The Prior Issuance Of Common Stock Upon At The Market Sales Net
ReimbursementOfCommissionsFromThePriorIssuanceOfCommonStockUponAtTheMarketSalesNet
46000
svra Repurchase Of Shares For Minimum Tax Withholdings
RepurchaseOfSharesForMinimumTaxWithholdings
4000
svra Repurchase Of Shares For Minimum Tax Withholdings
RepurchaseOfSharesForMinimumTaxWithholdings
1000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
104000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
130000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-17000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-86000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2721000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29355000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26585000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
52100000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23864000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22745000
us-gaap Interest Paid Net
InterestPaidNet
1078000
us-gaap Interest Paid Net
InterestPaidNet
973000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-436000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43100000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23900000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
97700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management’s estimates include, but are not limited to, those related to the accrual and prepayment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> of research and development expenses and general and administrative costs, certain financial instruments recorded at fair value, stock-based compensation, and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, changes in circumstance and facts, and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Accordingly, actual results could be materially different from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalents and marketable securities with a limited number of financial institutions. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q2 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
4268000
CY2023Q4 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
2167000
CY2024Q2 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
790000
CY2023Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
814000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
162000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
176000
CY2024Q2 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
226000
CY2023Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
191000
CY2024Q2 svra Deferred Financing Costs Current
DeferredFinancingCostsCurrent
325000
CY2024Q2 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
407000
CY2023Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
280000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6178000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3628000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1826000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4046000
CY2024Q2 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
4543000
CY2023Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2166000
CY2024Q2 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
1379000
CY2023Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
738000
CY2024Q2 svra Accrued Lease Liability
AccruedLeaseLiability
152000
CY2023Q4 svra Accrued Lease Liability
AccruedLeaseLiability
143000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7900000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7093000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
97738000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
87000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
97652000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
135541000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
194000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
135734000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
17667000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
17667000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
9562000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
9562000
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
27229000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
27229000
CY2024Q2 svra Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
408000
CY2023Q4 svra Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
482000
CY2024Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
309000
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
366000
CY2024Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
28000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
33000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
26484000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
26348000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26484000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26348000
svra Increase Decrease In Process Research And Development Due To Foreign Currency Translation
IncreaseDecreaseInProcessResearchAndDevelopmentDueToForeignCurrencyTranslation
-300000
svra Increase Decrease In Process Research And Development Due To Foreign Currency Translation
IncreaseDecreaseInProcessResearchAndDevelopmentDueToForeignCurrencyTranslation
100000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023Q3 svra Proceeds From Issuance Of Common Stock And Pre Funded Warrants
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants
79994000
CY2023Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5120000
CY2023Q3 svra Net Proceeds After Deducting Underwriting Discounts Commissions And Other Estimated Offering Expenses
NetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOtherEstimatedOfferingExpenses
74874000
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
57770313
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
57596486
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
44475169
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-605000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
334000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-271000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-609000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-880000
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
1836000
CY2024Q2 svra Estimated Service Fees
EstimatedServiceFees
20000000
CY2021Q1 svra Estimated Parexel Service Fees And Pass Through Expenses And Investigator Fees
EstimatedParexelServiceFeesAndPassThroughExpensesAndInvestigatorFees
42500000
CY2024Q2 svra Maximum Amount Of Earnings In Milestone Payment
MaximumAmountOfEarningsInMilestonePayment
3600000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9633067
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
230000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
62736
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
65312
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9735019
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3488250
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
142500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
3125
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
67500
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3560125
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2196000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
958000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4453000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1822000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13372937
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10997098
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-22243000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11443000
us-gaap Net Income Loss
NetIncomeLoss
-42589000
us-gaap Net Income Loss
NetIncomeLoss
-22000000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22243000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11443000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42589000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22000000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-22243000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11443000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-42589000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-22000000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182584078
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182584078
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152796617
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152796617
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182567091
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182567091
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152778031
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152778031
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-095403-index-headers.html Edgar Link pending
0000950170-24-095403-index.html Edgar Link pending
0000950170-24-095403.txt Edgar Link pending
0000950170-24-095403-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img199014270_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
svra-20240630.htm Edgar Link pending
svra-20240630.xsd Edgar Link pending
svra-ex31_1.htm Edgar Link pending
svra-ex31_2.htm Edgar Link pending
svra-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
svra-20240630_htm.xml Edgar Link completed